Press Release
<p>NEW ARTICLE REVEALS TREND TOWARD GREATER USE OF HUMAN MENOPAUSAL GONADOTROPIN IN <em>IN VITRO</em> FERTILIZATION</p>
<p><strong>Review Article of hMG Published in US <em>Obstetrics & Gynecology</em></strong></p>
<p><strong>PARSIPPANY, NJ – March 8, 2010 – </strong>The U.S. infertility specialty has empirically incorporated greater amounts of human menopausal gonadotropin (hMG) into stimulation protocols, according to a new review article, “Gonadotropins in the Treatment of Infertility” by George T. Koulianos, MD, published in a recent issue of US Obstetrics & Gynecology, supported by an educational grant from Ferring Pharmaceuticals.<sup>1</sup> The article reviews the wealth of clinical evidence supporting this trend, and demonstrates how the use of gonadotropins in the treatment of infertility, especially in assisted reproductive technologies, has significantly improved outcomes.</p>
<p>“Gonadotropins…have been especially important in improving the efficiency of in vitro fertilization,” said Dr. Koulianos. “The many large, complex studies conducted over the past decade demonstrate the unique attributes of hMG, especially highly purified hMG, that lead to better outcomes. The study results parallel the steady increase in the use of hMG, indicating that the field has empirically chosen hMG as its base of stimulation.”</p>
<p>Here are highlights from the article:</p>
<ul>
<li>For the approval of MENOPUR<sup>®</sup> (menotropins for injection, USP) (HP-hMG), based on results of the largest IVF trial ever conducted (EISG)<sup>2</sup>, trends favored hMG over recombinant follicle stimulating hormone (rFSH) in pregnancy rates, although there was no statistical significance. A post-hoc analysis of the study by Platteau et al.<sup>3</sup> suggested that hMG outperformed rFSH in IVF, and when intracytoplasmic sperm injection (ICSI) was used, the two treatments appeared to be equivalent. In this post-hoc analysis, lower pregnancy rates were seen in patients with lower serum hCG levels.</li>
<li>The Menotrophin versus Recombinant FSH in vitro Fertilization Trial (MERiT), the most extensive IVF study ever performed to date, with 731 patients, demonstrated significant differences in endocrine profile, a more natural stimulation with hMG, and greater capacity for pregnancy and live births from hMG-stimulated oocytes.</li>
</ul>
<p align="center"><img src="http://www.bytepush.com/ferringusa/pr/img.png" height="440" width="750" alt=""></p>
<ul>
<li>The Weghofer I study showed a greater number of cytogenetically normal embryos when hMG was used compared with the rFSH group (59.8+26.7 versus 45.3+26.5).</li>
</ul>
<p><strong>About MENOPUR<sup>®</sup> </strong></p>
<p>MENOPUR<sup>®</sup> administered subcutaneously is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an ART program.
Important Safety Information
Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe MENOPUR<sup>®</sup>. MENOPUR<sup>®</sup> is a potent substance capable of causing mild to severe adverse reactions, including OHSS (overall incidence 3.8%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. MENOPUR<sup>®</sup> is contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; sex hormone dependent tumors of the reproductive tract and accessory organs; abnormal uterine bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to menotropins or MENOPUR<sup>®</sup>. MENOPUR<sup>®</sup>
is not indicated in women who are pregnant. There are limited human data on the effects of menotropins when administered during pregnancy.</p>
<p>Please visit <a href="http://www.ferringfertility.com">www.ferringfertility.com</a> for Full Prescribing Information for MENOPUR<sup>®</sup>.</p>
EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used in people who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.
Important Safety Information
You should not receive this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products. You should not have an injection into the knee if you have a knee joint infection or if you have skin disease or infection around the injection site.
EUFLEXXA is only for injection into the knee performed by a qualified doctor. After you receive this injection you may need to avoid activities such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour). The safety and effectiveness of repeat treatment cycles of EUFLEXXA have not been established. The safety and effectiveness of EUFLEXXA have not been shown in people under 18 years of age.
Side effects sometimes seen when EUFLEXXA is injected into the knee joint were pain, swelling, skin irritation, and tenderness and these were generally mild and did not last long.
Please see Full Prescribing Information.
Please see Important Information for Patients.
Patient Treatment Information
PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE.
This website is intended only for US residents.
Euflexxa® is a registered trademark of Ferring Pharmaceuticals Inc.
